

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **May 20, 2025**

**SYRA HEALTH CORP.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-41822**  
(Commission  
File Number)

**85-4027995**  
(I. R. S. Employer  
Identification No.)

**1119 Keystone Way N. #201**  
**Carmel, IN 46032**  
(Address of principal executive offices, including zip code)

**(463) 345-8950**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| <b>Title of each class</b>              | <b>Trading Symbol(s)</b> | <b>Name of each exchange on which registered</b> |
|-----------------------------------------|--------------------------|--------------------------------------------------|
| Class A Common Stock, \$0.001 par value | SYRA                     | OTCQB                                            |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934

(§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

### **Item 8.01 Other Events.**

On May 20, 2025, Syra Health Corp. issued a press release announcing that its Board of Directors will begin a national search for a new Chief Executive Officer to succeed current CEO Dr. Deepika Vuppalanchi. Dr. Vuppalanchi will serve as interim CEO until a successor is appointed. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

### **Item 9.01 Financial Statements and Exhibit**

(d) Exhibits.

The following exhibits are filed with this Current Report on Form 8-K:

| <b>Exhibit<br/>Number</b> | <b>Description</b>                                                          |
|---------------------------|-----------------------------------------------------------------------------|
| 99.1                      | <a href="#">Press Release dated May 20, 2025</a>                            |
| 104                       | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

- 2 -

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**SYRA HEALTH CORP.**

Date: May 20, 2025

By: */s/ Deepika Vuppalanchi*  
Deepika Vuppalanchi  
Interim Chief Executive Officer

- 3 -